Acne Vulgaris (AV) - Market Insights, Epidemiology and Market Forecast to 2023

Description:

Acne vulgaris is a common chronic skin disease/Disorder of pilosebaceous follicles. The disease is characterized by blockage and/or inflammation of hair follicles and their accompanying sebaceous gland. Acne develops in regions of high sebaceous gland.

The disease is seen to occur mostly in adolescence. At puberty androgens due to the increase in sebum production from enlarged sebaceous glands, the glands become blocked. Propionibacterium acnes further colonise and lead to lesion production although its exact role is unclear.

“Acne Vulgaris (AV) - Market Insights, Epidemiology and Market Forecast - 2023” report provides an overview of the disease and market size of the Acne Vulgaris for the global, United States, EU5 (France, Germany, Italy, Spain and United Kingdom) and Japan for 2013-2023. It also includes global historical and forecasted epidemiological data for the Acne Vulgaris Diagnosed Cases from 2013-2023.

According to research, the Diagnosed cases in 7 major markets for Acne Vulgaris (AV) were 113,959,366 cases in 2013 and are expected to be 136,929,289 cases in 2023.

As per estimations, the global market size of Acne Vulgaris (AV) was USD 5,360.1 Million in 2013 and is expected to reach USD 14,226.3 Million by the end of 2023.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by our team of industry experts.

Scope:

- Report covers the disease overview including pathophysiology, symptoms, diagnosis, disease management, and current treatment options
- Marketed information including available prescription drugs
- The Report also covers the detailed global historical and forecasted epidemiological data covering United States, EU5 and Japan from 2013-2023
- It also provides Market size of Acne Vulgaris (AV) for United States, EU5 and Japan from 2013 and forecasted Market size to 2023

Contents:

Report Introduction
Acne Vulgaris Market Overview at a Glance
Total Market Size of Acne Vulgaris for 7 MM in 2010-2023
Total Market Share Distribution of Acne Vulgaris for 7 MM in 2015
Total Market Share Distribution of Acne Vulgaris for 7 MM in 2023
Acne Vulgaris Overview
Signs and symptoms
Types of Acne
Pathophysiology
Diagnosis
Epidemiology and Patient Population
- United States
Diagnosed Cases of Acne Vulgaris in United States
- Germany
Diagnosed Cases of Acne Vulgaris in Germany
- France
Diagnosed Cases of Acne Vulgaris in France
- United Kingdom
Diagnosed Cases of Acne Vulgaris in United Kingdom
- Spain
Diagnosed Cases of Acne Vulgaris in Spain
- Italy
- Japan
- Japan
Diagnosed Cases of Acne Vulgaris in Japan
Treatment Algorithm
Marketed Drugs
Top Marketed Drugs for Acne Vulgaris
- Acanya: Valeant Pharmaceuticals
Drug Description
Mechanism of Action
Regulatory Milestones
Advantages & Disadvantages
Safety and Efficacy of Acanya
Product Profile
- Tazorac: Allergan
Drug Description
Mechanism of Action
Regulatory Milestones
Advantages & Disadvantages
Safety and Efficacy of Tazorac
Product Profile
- Veltin: Almirall, S.A.
Drug Description
Mechanism of Action
Regulatory Milestones
Advantages & Disadvantages
Product Profile
- Duac: Glaxosmithkline
Drug Description
Mechanism of Action
Regulatory Milestones
Advantages & Disadvantages
Product Profile
- Epiduo and Epiduo Forte: Galderma S.A.
Drug Description
Mechanism of Action
Regulatory Milestones
Advantages & Disadvantages
Safety and Efficacy of Epiduo
Product Profile
Emerging Therapies
Major Pipeline drugs
- Sarecycline: Paratek Pharmaceuticals
Regulatory Milestones
Advantages & Disadvantages
Product Profile
Clinical Development
Clinical Pipeline Activity
Ongoing Trials Information
Clinical Trial by Phase
- Aczone reform: Allergan
Advantages & Disadvantages
Product Profile
- SB204: Novan, Inc.
Advantages & Disadvantages
Product Profile
Clinical Development
Clinical Pipeline Activity
Ongoing Trials Information
Clinical Trial by Phase
Global Acne Vulgaris: Country-Wise Market Analysis
Overview on Total Acne Vulgaris Market (2015)
Overview on Total Acne Vulgaris Market (2023)

United States Market Size
Europe Market Size
United Kingdom Market Size
Germany Market Size
France Market Size
Italy Market Size
Spain Market Size
Japan Market Size
Market Drivers
Market Restraints
Appendix
Report Methodology
Consulting Services
Disclaimer
About Us

List of Tables:
Table 1: Diagnosed Cases Acne Vulgaris in United States (2013-2023)
Table 2: Diagnosed Cases Acne Vulgaris in Germany (2013-2023)
Table 3: Diagnosed Cases Acne Vulgaris in France (2013-2023)
Table 4: Diagnosed Cases Acne Vulgaris in United Kingdom (2013-2023)
Table 5: Diagnosed Cases Acne Vulgaris in Spain (2013-2023)
Table 6: Diagnosed Cases Acne Vulgaris in Italy (2013-2023)
Table 7: Diagnosed Cases Acne Vulgaris in Japan (2013-2023)
Table 8: List of Marketed Drugs for Acne Vulgaris
Table 9: List of Pipeline Phase III Drugs for Acne Vulgaris
Table 10: Sarecycline, Clinical Trials by Zone, 2017
Table 11: Clinical Trials by Trial status, 2017
Table 12: SB204, Clinical Trials by Zone, 2017
Table 13: Clinical Trials by Trial status, 2017
Table 14: United States Market Size of Acne Vulgaris in USD, Million (2013-2023)
Table 15: United Kingdom Market Size of Acne Vulgaris in USD, Million (2013-2023)
Table 16: Germany Market Size of Acne Vulgaris in USD, Million (2013-2023)
Table 17: France Market Size of Acne Vulgaris in USD, Million (2013-2023)
Table 18: Italy Market Size of Acne Vulgaris in USD, Million (2013-2023)
Table 19: Spain Market Size of Acne Vulgaris in USD, Million (2013-2023)
Table 20: Japan Market Size of Acne Vulgaris in USD, Million (2013-2023)

List of Figures:
Figure 1: Cellular mechanisms hypothesized to govern the pathogenesis of Acne Vulgaris
Figure 2: Diagnosed Cases of Acne Vulgaris in United States (2013-2023)
Figure 3: Diagnosed Cases of Acne Vulgaris in Germany (2013-2023)
Figure 4: Diagnosed Cases of Acne Vulgaris in France (2013-2023)
Figure 5: Diagnosed Cases of Acne Vulgaris in United Kingdom (2013-2023)
Figure 6: Diagnosed Cases of Acne Vulgaris in Spain (2013-2023)
Figure 7: Diagnosed Cases of Acne Vulgaris in Italy (2013-2023)
Figure 8: Diagnosed Cases of Acne Vulgaris in Japan (2013-2023)
Figure 9: Sarecycline, Clinical Trials by Zone (%), 2017
Figure 10: Sarecycline, Clinical Trials by Trial status (%), 2017
Figure 11: SB204, Clinical Trials by Zone (%), 2017
Figure 12: SB204, Clinical Trials by Trial status (%), 2017
Figure 13: Total Market Size of Acne Vulgaris in USD, Million (2015)
Figure 14: Total Market Size of Acne Vulgaris in USD, Million (2023)
Figure 15: United States Market Size of Acne Vulgaris in USD, Million (2013-2023)
Figure 16: United Kingdom Market Size of Acne Vulgaris in USD, Million (2013-2023)
Figure 17: Germany Market Size of Acne Vulgaris in USD, Million (2013-2023)
Figure 18: France Market Size of Acne Vulgaris in USD, Million (2013-2023)
Figure 19: Italy Market Size of Acne Vulgaris in USD, Million (2013-2023)
Figure 20: Spain Market Size of Acne Vulgaris in USD, Million (2013-2023)
Figure 21: Japan Market Size of Acne Vulgaris in USD, Million (2013-2023)
Ordering:

Order Online - http://www.researchandmarkets.com/reports/4085568/

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Acne Vulgaris (AV) - Market Insights, Epidemiology and Market Forecast to 2023
Web Address: http://www.researchandmarkets.com/reports/4085568/
Office Code: SC

Product Formats
Please select the product formats and quantity you require:

Quantity

<table>
<thead>
<tr>
<th>Format</th>
<th>Description</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td></td>
<td>USD 4950</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License</td>
<td></td>
<td>USD 9900</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td></td>
<td>USD 14850</td>
</tr>
</tbody>
</table>

* The price quoted above is only valid for 30 days. Please submit your order within that time frame to avail of this price as all prices are subject to change.

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [ ] Mr  [ ] Mrs  [ ] Dr  [ ] Miss  [ ] Ms  [ ] Prof
First Name: ___________________________ Last Name: ___________________________
Email Address: * ___________________________
Job Title: ___________________________
Organisation: ___________________________
Address: ___________________________
City: ___________________________
Postal / Zip Code: ___________________________
Country: ___________________________
Phone Number: ___________________________
Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ________________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World